Literature DB >> 21357834

Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease.

Robyn A Honea1, Russell H Swerdlow, Eric D Vidoni, Jeffrey M Burns.   

Abstract

OBJECTIVE: Beyond age, having a family history is the most significant risk factor for Alzheimer disease (AD). This longitudinal brain imaging study examines whether there are differential patterns of regional gray matter atrophy in cognitively healthy elderly subjects with (FH+) and without (FH-) a family history of late-onset AD.
METHODS: As part of the KU Brain Aging Project, cognitively intact individuals with a maternal history (FHm, n = 11), paternal history (FHp, n = 10), or no parental history of AD (FH-, n = 32) similar in age, gender, education, and Mini-Mental State Examination (MMSE) score received MRI at baseline and 2-year follow-up. A custom voxel-based morphometry processing stream was used to examine regional differences in atrophy between FH groups, controlling for age, gender, and APOE ε4 (APOE4) status. We also analyzed APOE4-related atrophy.
RESULTS: Cognitively normal FH+ individuals had significantly increased whole-brain gray matter atrophy and CSF expansion compared to FH-. When FH+ groups were split, only FHm was associated with longitudinal measures of brain change. Moreover, our voxel-based analysis revealed that FHm subjects had significantly greater atrophy in the precuneus and parahippocampus/hippocampus regions compared to FH- and FHp subjects, independent of APOE4 status, gender, and age. Individuals with an ε4 allele had more regional atrophy in the frontal cortex compared to ε4 noncarriers.
CONCLUSIONS: We conclude that FHm individuals without dementia have progressive gray matter volume reductions in select AD-vulnerable brain regions, specifically the precuneus and parahippocampal gyrus. These data complement and extend reports of regional cerebral metabolic differences and increases in amyloid-β burden in FHm subjects, which may be related to a higher risk for developing AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357834      PMCID: PMC3053329          DOI: 10.1212/WNL.0b013e31820e7b74

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

1.  Image registration using a symmetric prior--in three dimensions.

Authors:  J Ashburner; J L Andersson; K J Friston
Journal:  Hum Brain Mapp       Date:  2000-04       Impact factor: 5.038

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study.

Authors:  L Adrienne Cupples; Lindsay A Farrer; A Dessa Sadovnick; Norman Relkin; Peter Whitehouse; Robert C Green
Journal:  Genet Med       Date:  2004 Jul-Aug       Impact factor: 8.822

4.  Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.

Authors:  Lisa Mosconi; Juha O Rinne; Wai H Tsui; Valentina Berti; Yi Li; Huiyu Wang; John Murray; Noora Scheinin; Kjell Någren; Schantel Williams; Lidia Glodzik; Susan De Santi; Shankar Vallabhajosula; Mony J de Leon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

5.  Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort.

Authors:  Shannon L Risacher; Li Shen; John D West; Sungeun Kim; Brenna C McDonald; Laurel A Beckett; Danielle J Harvey; Clifford R Jack; Michael W Weiner; Andrew J Saykin
Journal:  Neurobiol Aging       Date:  2010-08       Impact factor: 4.673

6.  The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation.

Authors:  Sterling C Johnson; Taylor W Schmitz; Mehul A Trivedi; Michele L Ries; Britta M Torgerson; Cynthia M Carlsson; Sanjay Asthana; Bruce P Hermann; Mark A Sager
Journal:  J Neurosci       Date:  2006-05-31       Impact factor: 6.167

7.  Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.

Authors:  Gaël Chételat; Victor L Villemagne; Pierrick Bourgeat; Kerryn E Pike; Gareth Jones; David Ames; Kathryn A Ellis; Cassandra Szoeke; Ralph N Martins; Graeme J O'Keefe; Olivier Salvado; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

8.  Effects of ApoE4 and maternal history of dementia on hippocampal atrophy.

Authors:  John P Andrawis; Kristy S Hwang; Amity E Green; Jenny Kotlerman; David Elashoff; Jonathan H Morra; Jeffrey L Cummings; Arthur W Toga; Paul M Thompson; Liana G Apostolova
Journal:  Neurobiol Aging       Date:  2010-09-15       Impact factor: 4.673

9.  Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly.

Authors:  Yvette I Sheline; Marcus E Raichle; Abraham Z Snyder; John C Morris; Denise Head; Suzhi Wang; Mark A Mintun
Journal:  Biol Psychiatry       Date:  2009-10-14       Impact factor: 13.382

Review 10.  Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes.

Authors:  Lisa Mosconi; Valentina Berti; Russell H Swerdlow; Alberto Pupi; Ranjan Duara; Mony de Leon
Journal:  Hum Genomics       Date:  2010-02       Impact factor: 4.639

View more
  47 in total

1.  Maternal family history is associated with Alzheimer's disease biomarkers.

Authors:  Robyn A Honea; Eric D Vidoni; Russell H Swerdlow; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Role of mitochondrial homeostasis and dynamics in Alzheimer's disease.

Authors:  J Eva Selfridge; Lezi E; Jianghua Lu; Russell H Swerdlow
Journal:  Neurobiol Dis       Date:  2012-01-10       Impact factor: 5.996

3.  Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.

Authors:  Lisa Mosconi; Juha O Rinne; Wai H Tsui; John Murray; Yi Li; Lidia Glodzik; Pauline McHugh; Schantel Williams; Megan Cummings; Elizabeth Pirraglia; Stanley J Goldsmith; Shankar Vallabhajosula; Noora Scheinin; Tapio Viljanen; Kjell Någren; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2012-04-11       Impact factor: 4.673

4.  Maternal transmission of Alzheimer disease.

Authors:  Kristin A Heggeli; Julia Crook; Colleen Thomas; Neill Graff-Radford
Journal:  Alzheimer Dis Assoc Disord       Date:  2012 Oct-Dec       Impact factor: 2.703

5.  Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults.

Authors:  O C Okonkwo; G Xu; N M Dowling; B B Bendlin; A Larue; B P Hermann; R Koscik; E Jonaitis; H A Rowley; C M Carlsson; S Asthana; M A Sager; S C Johnson
Journal:  Neurology       Date:  2012-05-16       Impact factor: 9.910

Review 6.  The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  Biochim Biophys Acta       Date:  2013-09-23

Review 7.  Structural imaging in early pre-states of dementia.

Authors:  Charles D Smith
Journal:  Biochim Biophys Acta       Date:  2011-07-14

8.  Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD.

Authors:  Lisa Mosconi; John Murray; Wai H Tsui; Yi Li; Nicole Spector; Alexander Goldowsky; Schantel Williams; Ricardo Osorio; Pauline McHugh; Lidia Glodzik; Shankar Vallabhajosula; Mony J de Leon
Journal:  Neurology       Date:  2014-02-12       Impact factor: 9.910

Review 9.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

Review 10.  Advances in longitudinal studies of amnestic mild cognitive impairment and Alzheimer's disease based on multi-modal MRI techniques.

Authors:  Zhongjie Hu; Liyong Wu; Jianping Jia; Ying Han
Journal:  Neurosci Bull       Date:  2014-02-27       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.